Insider Selling: Assembly Biosciences (NASDAQ:ASMB) Insider Sells $50,874.66 in Stock

Assembly Biosciences, Inc. (NASDAQ:ASMB) insider Nicole White sold 2,593 shares of Assembly Biosciences stock in a transaction on Monday, November 2nd. The stock was sold at an average price of $19.62, for a total transaction of $50,874.66. Following the completion of the transaction, the insider owned 59,257 shares in the company, valued at approximately $1,162,622.34. The trade was a 4.19% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through this hyperlink. The sale was made to cover tax withholding obligations related to the vesting of equity awards.

Assembly Biosciences Stock Up 0.7%

Assembly Biosciences stock opened at $20.00 on Friday. The firm has a fifty day simple moving average of $24.92 and a two-hundred day simple moving average of $27.02. Assembly Biosciences, Inc. has a twelve month low of $19.20 and a twelve month high of $39.71. The company has a market capitalization of $407.20 million, a PE ratio of 19.48 and a beta of 1.26.

Assembly Biosciences (NASDAQ:ASMB) last announced its quarterly earnings data on Thursday, August 13th. The biopharmaceutical company reported ($0.20) earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of ($0.72) by $0.52. The firm had revenue of $13.37 million for the quarter, compared to analysts’ expectations of $8.60 million. Assembly Biosciences had a negative return on equity of 0.02% and a negative net margin of 0.06%. As a group, equities analysts expect that Assembly Biosciences, Inc. will post 2.28 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Assembly Biosciences

Several hedge funds and other institutional investors have recently modified their holdings of ASMB. Seven Fleet Capital Management LP grew its stake in shares of Assembly Biosciences by 671.5% in the second quarter. Seven Fleet Capital Management LP now owns 433,147 shares of the biopharmaceutical company’s stock worth $11,903,000 after purchasing an additional 377,000 shares during the last quarter. Stempoint Capital LP increased its holdings in Assembly Biosciences by 18.3% during the 1st quarter. Stempoint Capital LP now owns 185,435 shares of the biopharmaceutical company’s stock valued at $5,146,000 after purchasing an additional 28,707 shares during the period. Bank of New York Mellon Corp bought a new position in Assembly Biosciences during the 2nd quarter valued at approximately $660,000. Janus Henderson Group PLC raised its position in Assembly Biosciences by 1.4% during the 1st quarter. Janus Henderson Group PLC now owns 849,309 shares of the biopharmaceutical company’s stock valued at $23,479,000 after purchasing an additional 11,384 shares during the last quarter. Finally, Squarepoint Ops LLC raised its position in Assembly Biosciences by 43.7% during the 2nd quarter. Squarepoint Ops LLC now owns 34,214 shares of the biopharmaceutical company’s stock valued at $940,000 after purchasing an additional 10,410 shares during the last quarter. 19.92% of the stock is owned by institutional investors.

Analyst Ratings Changes

ASMB has been the topic of a number of analyst reports. Mizuho set a $53.00 price target on Assembly Biosciences in a research note on Tuesday, September 1st. UBS Group lowered their price objective on Assembly Biosciences from $52.00 to $48.00 and set a “buy” rating for the company in a research report on Tuesday. Zacks Research raised Assembly Biosciences from a “hold” rating to a “strong-buy” rating in a research note on Thursday, August 20th. Weiss Ratings restated a “sell (d-)” rating on shares of Assembly Biosciences in a report on Thursday, October 15th. Finally, HC Wainwright restated a “buy” rating and issued a $50.00 target price on shares of Assembly Biosciences in a report on Tuesday, August 18th. One analyst has rated the stock with a Strong Buy rating, four have issued a Buy rating and one has assigned a Sell rating to the company’s stock. According to data from MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $46.50.

Assembly Biosciences Company Profile

Assembly Biosciences, Inc is a clinical-stage biotechnology company focused on developing oral therapeutics for serious viral infections. The company’s research programs target chronic hepatitis B virus (HBV) infection and herpesvirus infections, including herpes simplex virus (HSV), with the goal of addressing diseases for which existing treatments may not provide adequate cures or long-term control.

Assembly’s pipeline includes novel antiviral candidates designed to interfere with essential stages of viral replication.